# 503A and 503B: how compounding oversight differs

What the two U.S. compounding frameworks mean for prescriptions, facility oversight and manufacturing requirements.

Canonical: https://velri.co/blog/compounded-quality-oversight-myth-results-driven-owner-michael
Publisher: Velri (https://velri.co/about)
Published: 2026-07-21
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

503A and 503B refer to sections of federal law that establish different conditions for drug compounding. They describe regulatory frameworks, not grades of effectiveness.

Compounded drugs under either framework are not FDA-approved. FDA does not review the finished preparations for safety, effectiveness or quality before they are marketed. [1]

## 503A: generally patient-specific compounding

Section 503A applies to compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, when the relevant legal conditions are met. The framework generally involves an individual patient's prescription. [1][4]

State boards of pharmacy ordinarily have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities. FDA also conducts surveillance and for-cause inspections of these pharmacies. [1]

Drugs compounded in accordance with 503A conditions are exempt from certain federal requirements, including current good manufacturing practice requirements. Other requirements still apply, including the prohibition on preparing drugs under insanitary conditions. [1]

## 503B: registered outsourcing facilities

An outsourcing facility elects to register with FDA under section 503B and must meet that section's conditions. Its compounded drugs remain subject to current good manufacturing practice requirements. [2]

These facilities are inspected by FDA on a risk-based schedule. They must also meet reporting requirements, including reporting adverse events and information about the products they compound. [2]

Registration is a facility status. It does not give every medication made there FDA approval.

## How this helps with an actual prescription

Knowing the framework helps identify which oversight and manufacturing requirements apply. It does not settle whether a particular medication is appropriate, whether a claimed benefit is supported or whether a specific product has a quality problem.

FDA has documented serious problems with compounded drugs, including contamination and incorrect amounts of active ingredient. The relevant question is how the particular preparation is sourced, made, labeled and followed up, alongside the medical reason for prescribing it. [1][3]

For a proposed order, verify the facility’s identity and the specific preparation. An “FDA registered” claim describes the facility; it does not mean the compounded medication is FDA-approved.

## Sources
[1] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
[2] Information for Outsourcing Facilities | FDA. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
[3] Understanding the Risks of Compounded Drugs | FDA. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs
[4] FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support